Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK , Nov. 26, 2014 ... growing at a rate of 4%, with world ... to Kalorama Information. MRI and other types of ... diagnosis and treatment of numerous medical conditions in ... technologies and techniques. Kalorama,s report, Medical Imaging ...
(Date:11/26/2014)... 2014  goBalto, Inc., the leading provider of cloud-based ... winner of Red Herring,s Top 100 Global ... America award in 2013, marking its emergence as a ... Red Herring,s Top 100 Global list has become a ... entrepreneurs. Red Herring editors were among the first to ...
(Date:11/26/2014)...   Heska Corporation (NASDAQ: HSKA ) ... of advanced veterinary diagnostic and other specialty veterinary products ... will attend The Benchmark Company, LLC,s Micro Cap Discovery Conference ... held at The Palmer House Hilton, 17 E. Monroe Street, ... 2:30 p.m. Please email hska@haydenir.com or contact your ...
Breaking Medicine Technology:Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2
... Medical Affairs function arguably plays the most critical ... across areas such as clinical development, scientific publications, ... operate effectively for new products to succeed. Appropriate ... challenges facing the Medical Affairs function as it ...
... radiosurgery treatment for prostate cancer is rapid, effective and has ... Since 2003, the CyberKnife Center of Miami and the CyberKnife ... cancer treatment longer than any facility in South Florida. ( ... more than a quarter of a million men each year ...
Cached Medicine Technology:Medical Affairs Report Outlines Resource Needs for Group Success 2CyberKnife Treatment for Prostate Cancer 2
(Date:11/26/2014)... 2014 Increasing demand for diagnostic ... guided surgeries has paved way for consequent increase ... of various types of cancers and cardiac diseases ... demand for these owing to their use in ... injectors market can also be attributed to advancements ...
(Date:11/26/2014)... 2014 Gone are the days when throngs ... Black Friday, which signifies the beginning of the Christmas shopping ... shopping carts in the comfort of their homes or on ... Friday is going to be an occasion with one of ... estimated $2.48 billion in revenue for online retailers according to ...
(Date:11/26/2014)... November 26, 2014 With a redesign ... Dr. Steven Meier has enhanced the user experience ... and prospective patients an online destination for orthopedic and ... to present the new and improved version of the ... it easier than ever for current and prospective patients ...
(Date:11/26/2014)... November 26, 2014 Sonru, the video ... new Chief Operating Officer and Chief Marketing Officer, in ... office. , Jeff Jones has been appointed as ... who takes the role of Chief Marketing Officer. , ... executive whose 25-year career includes senior roles with The ...
(Date:11/26/2014)... 26, 2014 Medical suction and vacuum ... of 5. This score represents steady growth in the ... to 2014 as a result of swelling demand for ... which are largely considered nondiscretionary. IBISWorld market research analyst, ... have some degree of flexibility, given the low level ...
Breaking Medicine News(10 mins):Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:2014 Best Friday Deals Revealed by Top10InAction 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4
... provide both system and "board-only" leasing options to its clients. "If ... acquire the products they need, our feeling is that we,ve created ... True Data CEO, Andrew Palenscar. , ... Carlsbad, CA ...
... microtubule-binding protein Tau is not a reliable means of ... to research led by The University of Texas M. ... at the CRTC-AACR San Antonio Breast Cancer Symposium, the ... in an unexpected way. , In earlier ...
... to alert patients of the serious and potentially fatal health risks they ... directly exposed to the gel inside the patch, or who received an ... other serious and potentially fatal side effects. , ... Austin, Texas (PRWEB) ...
... seen, study says , , FRIDAY, Dec. 12 (HealthDay News) -- ... prove to be a valuable new weapon in the crusade ... drug, known as lorcaserin, resulted in substantial weight loss in ... novel mechanism and we think it can bring very robust ...
... make them more resilient during real attack, experts say , , ... known that the creation of a "mini heart attack" ... arteries -- can actually reduce the damage from a subsequent ... protective effect occurs, according to research from the University of ...
... are victorious in sham SEIU vote , Less ... while caregivers file over 125,000 protests , ... in a statewide vote of healthcare workers conducted by the ... workers overwhelmingly oppose their national union,s sham election. Ballots were ...
Cached Medicine News:Health News:True Data Offers New Special Leasing Rates on Dialogic, Samsung, & Vertical Communications Products 2Health News:Tau protein expression predicts breast cancer survival -- though not as expected 2Health News:Tau protein expression predicts breast cancer survival -- though not as expected 3Health News:Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks of Fentanyl Overdose 2Health News:Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks of Fentanyl Overdose 3Health News:Experimental Weight-Loss Pill Passes Early Test 2Health News:Experimental Weight-Loss Pill Passes Early Test 3Health News:Research Explains Benefit of 'Mini Heart Attack' 2Health News:Free Choice? Not For SEIU Members in California 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: